Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: A systematic review and a proposal

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2440-2446

  Agger, Morten ^a   Scheutz, Flemming ^b   Villumsen, Steen ^b   Mølbak, Kåre ^b   Petersen, Andreas Munk ^c  

^a Trelleborg Hospital   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ACUTE VEROCYTOTOXIN PRODUCING ESCHERICHIA COLI INFECTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CHRONIC VEROCYTOTOXIN PRODUCING ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI INFECTION; HEMOLYTIC UREMIC SYNDROME; HETEROZYGOTE; HUMAN; IN VITRO STUDY; INFECTION RISK; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPE; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; MICROBIOLOGY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; SHIGA-TOXIGENIC ESCHERICHIA COLI; TREATMENT OUTCOME;

EID: 84954304671     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv162     Document Type: Article

References (54)

1. Riley LW, Remis RS, Helgerson SD et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308: 681-5.
2. Scheutz F, Strockbine N, Genus I. Escherichia. In: Garrity G, ed. The Gammaproteobacteria. Bergey's Manual of Systematic Bacteriology. Berlin: Springer, 2005; 607-24.
3. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365: 1073-86.
4. Ethelberg S, Olsen KEP, Scheutz F et al. Virulence factors for hemolytic uremic syndrome, Denmark. Emerg Infect Dis 2004; 10: 842-7.
5. Persson S, Olsen KEP, Ethelberg S et al. Subtyping method for Escherichia coli shiga toxin (verocytotoxin) 2 variants and correlations to clinical manifestations. J Clin Microbiol 2007; 45: 2020-4.
6. Pedersen MG, Hansen C, Riise E et al. Subtype-specific suppression of Shiga toxin 2 released from Escherichia coli upon exposure to protein synthesis inhibitors. J Clin Microbiol 2008; 46: 2987-91.
7. Friedrich AW, Bielaszewska M, Zhang W-L et al. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis 2002; 185: 74-84.
8. Johnson KE, Thorpe CM, Sears CL. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis 2006; 43: 1587-95.
9. Safdar N, Said A, Gangnon RE et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002; 288: 996-1001.
10. Todd WT, Dundas S. The management of VTEC O157 infection. Int J Food Microbiol 2001; 66: 103-10.
11. Goldwater PN, Bettelheim KA. Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS). BMC Med 2012; 10: 12.
12. Olesen B, Jensen C, Olsen K et al. VTEC O117:K1:H7. A new clonal group of E. coli associated with persistent diarrhoea in Danish travellers. Scand J Infect Dis 2005; 37: 288-94.
13. Belongia EA, Osterholm MT, Soler JT et al. Transmission of Escherichia coli O157:H7 infection in Minnesota child day-care facilities. JAMA 1993; 269: 883-8.
14. Snedeker KG, Shaw DJ, Locking ME et al. Primary and secondary cases in Escherichia coli O157 outbreaks: a statistical analysis. BMC Infect Dis 2009; 9: 144.
15. Scheutz F, Teel LD, Beutin L et al. Multicenter evaluation of a sequencebased protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012; 50: 2951-63.
16. Proulx F, Turgeon JP, Delage G et al. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992; 121: 299-303.
17. Pavia AT, Nichols CR, Green DP et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990; 116: 544-51.
18. Slutsker L, Ries AA, Maloney K et al. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998; 177: 962-6.
19. Wong CS, Jelacic S, Habeeb RL et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930-6.
20. Wong CS, Mooney JC, Brandt JR et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012; 55: 33-41.
21. Dundas S, Todd WT, Stewart AI et al. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001; 33: 923-31.
22. Cimolai N, Carter JE, Morrison BJ et al. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990; 116: 589-92.
23. Cimolai N, Basalyga S, Mah DG et al. A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clin Nephrol 1994; 42: 85-9.
24. Ostroff SM, Kobayashi JM, Lewis JH. Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 1989; 262: 355-9.
25. Bell BP, Griffin PM, Lozano P et al. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997; 100: E12.
26. Ikeda K, Ida O, Kimoto K et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52: 357-62.
27. Smith KE, Wilker PR, Reiter PL et al. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J 2012; 31: 37-41.
28. Rasko DA, Webster DR, Sahl JW et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365: 709-17.
29. Bielaszewska M, Friedrich AW, Aldick T et al. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006; 43: 1160-7.
30. Mariani-Kurkdjian P, Denamur E, Milon A et al. Identification of a clone of Escherichia coli O103:H2 as a potential agent of hemolytic-uremic syndrome in France. J Clin Microbiol 1993; 31: 296-301.
31. Zhang X, McDaniel AD, Wolf LE et al. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181: 664-70.
32. Yoshimura K, Fujii J, Taniguchi H et al. Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. FEMS Immunol Med Microbiol 1999; 26: 101-8.
33. Isogai E, Isogai H, Hayashi S et al. Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol Immunol 2000; 44: 89-95.
34. Rahal EA, Kazzi N, Kanbar A et al. Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Int J Antimicrob Agents 2011; 37: 135-9.
35. Kurioka T, Yunou Y, Harada H et al. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Eur J Clin Microbiol Infect Dis 1999; 18: 561-71.
36. McGannon CM, Fuller CA, Weiss AA. Different classes of antibiotics differentially influence shiga toxin production. Antimicrob Agents Chemother 2010; 54: 3790-8.
37. Yoh M, Frimpong EK, Voravuthikunchai SP et al. Effect of subinhibitory concentrations of antimicrobial agents (quinolones and macrolide) on the production of verotoxin by enterohemorrhagic Escherichia coli O157:H7. Can J Microbiol 1999; 45: 732-9.
38. Murakami J, Kishi K, Hirai K et al. Macrolides and clindamycin suppress the release of Shiga-like toxins from Escherichia coli O157:H7 in vitro. Int J Antimicrob Agents 2000; 15: 103-9.
39. Ochoa TJ, Chen J, Walker CM et al. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 2007; 51: 2837-41.
40. Grif K, Dierich MP, Karch H et al. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998; 17: 761-6.
41. Walterspiel JN, Ashkenazi S, Morrow AL et al. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 20: 25-9.
42. Corogeanu D, Willmes R, Wolke M et al. Therapeutic concentrations of antibiotics inhibit Shiga toxin release from enterohemorrhagic E. coli O104:H4 from the 2011 German outbreak. BMC Microbiol 2012; 12: 160.
43. Bielaszewska M, Idelevich EA, Zhang W et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012; 56: 3277-82.
44. Ichinohe N, Ohara-Nemoto Y, Nemoto TK et al. Effects of fosfomycin on Shiga toxin-producing Escherichia coli: quantification of copy numbers of Shiga toxin-encoding genes and their expression levels using real-time PCR. J Med Microbiol 2009; 58: 971-3.
45. Nassar FJ, Rahal EA, Sabra A et al. Effects of subinhibitory concentrations of antimicrobial agents on Escherichia coli O157:H7 Shiga toxin release and role of the SOS response. Foodborne Pathog Dis 2013; 10: 805-12.
46. Ito T, Akino E, Hiramatsu K. [Evaluation of antibiotics used for enterohemorrhagic Escherichia coli O157 enteritis: effect of various antibiotics on extracellular release of verotoxin]. Kansenshogaku Zasshi 1997; 71: 130-5.
47. Sawamura S, Tanaka K, Koga Y. [Therapeutic effects of antibiotics against enterohemorrhagic Escherichia coli (EHEC) O157:H7 (O157) infection: in vivo analysis using germfree mice]. Kansenshogaku Zasshi 1999; 73: 1054-63.
48. Mohsin M, Haque A, Ali A et al. Effects of ampicillin, gentamicin, and cefotaxime on the release of Shiga toxins from Shiga toxin-producing Escherichia coli isolated during a diarrhea episode in Faisalabad, Pakistan. Foodborne Pathog Dis 2010; 7: 85-90.
49. Nakata K, Tozu T, Hoshikawa Y et al. [Suppressive effect of clarithromycin on the production of verotoxin by E. coli O157]. Kansenshogaku Zasshi 1997; 71: 437-42.
50. Takahashi K, Narita K, Kato Y et al. Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother 1997; 41: 2295-6.
51. Steyert SR, Sahl JW, Fraser CM et al. Comparative genomics and stx phage characterization of LEE-negative Shiga toxin-producing Escherichia coli. Front Cell Infect Microbiol 2012; 2: 133.
52. Chandler WL, Jelacic S, Boster DR et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32.
53. Jensen C, Schiellerup P, Olsen K et al. Antimicrobial treatment of asymptomatic carriers of verocytotoxin-producing Escherichia coli: an empiric study. Scand J Infect Dis 2005; 37: 61-3.
54. Nitschke M, Sayk F, Härtel C et al. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012; 307: 1046-52.